Skip to main content

Table 5 Changes in NEI-VFQ-25 subscale scores from baseline to 12 months in each baseline vision group (N=69)

From: Correlation between improvement in visual acuity and QOL after Ranibizumab treatment for age-related macular degeneration patients: QUATRO study

NEI VFQ-25 Subscale

Decimal visual acuity

Below 0.5

Above 0.6

CFB

95%CI

P value

CFB

95%CI

P value

Lower

Upper

Lower

Upper

Overall

5.9

3.2

8.5

0.00003

6.8

3.8

9.9

0.00002

General health

0.2

−5.2

5.7

0.93339

−1.7

−8.0

4.5

0.5804

General vision

9.3

4.0

14.5

0.00059

12.5

6.5

18.5

0.00006

Ocular pain

−0.1

−4.1

3.8

0.95172

0.9

−3.6

5.4

0.68663

Near activities

4.5

−0.8

9.9

0.09667

8.6

2.6

14.6

0.00561

Distance activities

2.9

−1.5

7.2

0.19592

5.7

0.7

10.6

0.02534

Social functioning

4.9

0.6

9.3

0.02557

7.0

2.1

11.9

0.00528

Mental health

16.8

11.8

21.7

0

6.1

0.5

11.7

0.03438

Role difficulties

11.4

5.3

17.5

0.00028

8.6

1.7

15.5

0.01487

Dependency

7.7

3.1

12.3

0.00116

5.0

−0.3

10.2

0.06256

Driving

−7.3

−14.9

0.3

0.05868

5.2

−2.1

12.6

0.16173

Color vision

2.1

−2.5

6.7

0.36726

3.8

−1.4

9.1

0.15108

Peripheral vision

3.9

−2.7

10.5

0.24607

6.8

−0.6

14.1

0.06986

  1. CFB Change from baseline, CI confidence interval, NEI-VFQ-25 25-item National Eye Institute Visual Function Questionnaire